The cancer monoclonal antibodies market share is expected to increase by USD 33.10 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 8.23%.

This cancer monoclonal antibodies market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers cancer monoclonal antibodies market segmentations by type (naked monoclonal antibodies and conjugated and bi-specific monoclonal antibodies) and geography (North America, Europe, Asia, and ROW). The cancer monoclonal antibodies market report also offers information on several market vendors, including Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Johnson and Johnson Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., and Sanofi SA among others.

What will the Cancer Monoclonal Antibodies Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Cancer Monoclonal Antibodies Market Size for the Forecast Period and Other Important Statistics

Cancer Monoclonal Antibodies Market: Key Drivers, Trends, and Challenges

Based on our research output, there has been a neutral impact on the market growth during and post COVID-19 era. The increase in demand for ADCs is notably driving the cancer monoclonal antibodies market growth, although factors such as complicated regulatory framework may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the cancer monoclonal antibodies industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Cancer Monoclonal Antibodies Market Driver

One of the key factors driving the cancer monoclonal antibodies market growth is the increase in demand for ADCs. Antibodies are increasingly becoming the preferred choice to treat diseases such as respiratory, oncology, and inflammatory diseases. Understanding diseases at a molecular level increases the development and use of antibodies. The use of ADCs, including radioimmunotherapy and antibody-directed enzyme prodrug therapy, is growing. The increasing use of these antibodies in drug development increases revenue generation in the global next-generation biologics market, thereby contributing to the cancer monoclonal antibodies market growth. ADCs were used over a century ago when the German physician and scientist Paul Ehrlich invented the concept of selectively transporting a cytotoxic drug to a tumor using a targeting agent. Almost 50 years later, this targeted therapy was first established when methotrexate was linked to an antibody to target leukemia cells. ADCs were previously used as murine polyclonal antibodies, which were more immunogenic. However, developments in antibody engineering have brought about the production of humanized monoclonal antibodies that have significantly avoided the issues of immunogenicity.

Key Cancer Monoclonal Antibodies Market Trend

Strategic alliances and partnerships for R&D is the major trend influencing cancer monoclonal antibodies market growth. Strategic alliances formed regarding collaboration and licensing will help co-develop and commercialize monoclonal antibodies worldwide. Co-development agreements enable the use of technical expertise from both companies to help them promote and support each other to develop and market the novel drugs. They also ensure the in-flow of adequate funds for the companies involved and reduce liability costs for individual companies in case of failures, thereby attracting more venture investments. For example, Seattle Genetics collaborated with Bristol-Myers Squibb to develop a combination of OPDIVO and ADCETRIS to treat hematologic malignancies. ADCETRIS, originally developed by Seattle Genetics, is now marketed in collaboration with Takeda Pharmaceuticals worldwide, except in the US and Canada. In context to the collaboration, in June 2019, Amgen and Allergan plc announced that the US FDA had approved KANJINTI (trastuzumab-anns) for all approved indications of HERCEPTIN (trastuzumab). It has been approved for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Such long partnerships are expected to further benefit the market growth.

Key Cancer Monoclonal Antibodies Market Challenge

Complicated regulatory framework is one of the key challenges hindering the cancer monoclonal antibodies market growth. Gaining regulatory approval is often difficult, unpredictable, and subjective. Biologics products must undergo a broad range of stringent regulations before approval and commercialization. Currently, the US FDA has approved very few products for stem cell therapy. However, there are several transplant centers running in the region that uses unapproved cell therapies. To curb this, the US FDA issued warning letters to many clinics such as Celltex, a stem cell clinic in Texas, US. Also, the US FDA has made certain guidelines for stem cell clinics for such usage. For instance, for these unapproved therapies, the cells should be grown under clinical conditions, and only a few products such as semen and vascular grafts can be used but only by licensed physicians. Such stringent regulatory systems are beneficial for the individuals, but on the other hand, it creates issues/hurdles toward the commercialization of underlying products, primarily relating to marketing approval and manufacturing.

This cancer monoclonal antibodies market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Parent Market Analysis

Technavio categorizes the global cancer monoclonal antibodies market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the cancer monoclonal antibodies market during the forecast period.

Who are the Major Cancer Monoclonal Antibodies Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca Plc
• Bristol Myers Squibb Co.
• F. Hoffmann La Roche Ltd.
• Johnson and Johnson Inc.
• Merck and Co. Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi SA

This statistical study of the cancer monoclonal antibodies market encompasses successful business strategies deployed by the key vendors. The cancer monoclonal antibodies market is fragmented and the vendors are deploying growth strategies such as investing in technologies to develop advanced biologic therapeutics, such as monoclonal antibodies to compete in the market.

Product Insights and News

• Amgen Inc. - The company offers BLINCYTO, which is blinatumomab, bispecific CD19 directed CD3 T cell engager, indicated for the treatment of B cell precursor acute lymphoblastic leukemia and Relapsed or refractory B cell precursor acute lymphoblastic leukemia. The company also offers Vectibix, which is fully human monoclonal antibody specific to the epidermal growth factor receptor used for the treatment of wild type RAS metastatic colorectal cancer.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The cancer monoclonal antibodies market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Cancer Monoclonal Antibodies Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the cancer monoclonal antibodies market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.

Which are the Key Regions for Cancer Monoclonal Antibodies Market?

For more insights on the market share of various regions Request for a FREE sample now!

55% of the market's growth will originate from North America during the forecast period. US is the key market for cancer monoclonal antibodies in North America. Market growth in this region will be slower than the growth of the market in Europe and Asia regions.

The US is the base for key players, such as AbbVie, Elli Lilly, Merck, Pfizer, and Amgen. These vendors have highly differentiated products, which have influenced both physicians and patients for their adoption. The increased incidence of various types of cancer in North America during the past few years has been driving the regional market's growth. The incidence rate is expected to rise further during the forecast period due to factors such as sedentary lifestyles, rising rates of obesity, and high smoking. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The cancer monoclonal antibodies market in North America witnessed low growth in 2020 due to the COVID-19 outbreak. The pandemic has impacted many businesses and economies in the region. The supply chain disruptions in the pharmaceutical industry, owing to lockdown situations, have hampered market growth in 2020. Also, the process of clinical trials slowed down as a major part of the focus was shifted toward developing COVID-19 vaccines. However, the market is expected to return to normalcy during the forecast years as the number of COVID-19 cases is reducing, and a major portion of the US population (42%) has been completely vaccinated.

What are the Revenue-generating Type Segments in the Cancer Monoclonal Antibodies Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The cancer monoclonal antibodies market share growth by the naked monoclonal antibodies will be significant during the forecast period. Naked monoclonal antibodies are the most commonly used monoclonal antibodies and are also known as targeted therapies. Some naked monoclonal antibodies do not interact with an individual's immune system. Its capability to attach to antigens of cancerous cells or other cells that help in the growth of cancer cells is the major factor in its success.

Besides the above-mentioned factors, the post COVID-19 impact has brought forth a slowdown in or fast tracked the demand for the service or product. This report provides an accurate prediction of the contribution of all the segments to the growth of the cancer monoclonal antibodies market size and actionable market insights on post COVID-19 impact on each segment.

Request for a FREE sample

What are the Key Data Covered in this Cancer Monoclonal Antibodies Market Report?

• CAGR of the market during the forecast period 2021-2025
• Detailed information on factors that will drive cancer monoclonal antibodies market growth during the next five years
• Precise estimation of the cancer monoclonal antibodies market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the cancer monoclonal antibodies industry across North America, Europe, Asia, and ROW
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of cancer monoclonal antibodies market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch